Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Esther J. Beck; Alexander D. Sherry; Marcus A. Florez; Ramez Kouzy; Joseph Abi Jaoude; Timothy A. Lin; Avital M. Miller; Adina H. Passy; Gabrielle S. Kupferman; Roshal R. Patel; Fumiko Chino; Victoria Serpas Higbie; Christine M. Parseghian; Michael J. Overman; Bruce D. Minsky; Charles R. Thomas; Chad Tang; Pavlos Msaouel; Ethan B. Ludmir

doi:10.1158/2767-9764.27101879

Key Points

Trial-level factors demonstrate significant associations with the overall publication rate of secondary endpoints across diverse phase III oncology trials.
Assessment using a full multivariable model evaluated the links between significant trial-level factors and the percentage of secondary endpoints published.
Highlights the necessity of tracking secondary endpoints systematically to improve transparency and reduce publication bias in phase iii oncology trials.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Multivariable analysis reveals trial-level factors associated with secondary endpoint publication rates in phase III oncology trials, highlighting reporting patterns.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beck et al. (2024) studied this question.

synapsesocial.com/papers/68e5778bb6db643587517181 https://doi.org/10.1158/2767-9764.27101879

View at Publisher

Ask AI

Bookmark

Share

Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading